Cogent Biosciences (COGT)

• Market cap: $651M
• 1 day: -1.21%
• 5 days: -12.27%
• 1 month: -18.29%
• 3 months: -26.67%
• 6 months: -46.64%
• Year to date: -26.67%
• 1 year: -15.26%
• 5 years: 308.57%
• 10 years: -87.13%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Employees: 205

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

57% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 23

37% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 46

14% more funds holding in top 10

Funds holding in top 10: 7 [Q3] → 8 (+1) [Q4]

7% more funds holding

Funds holding: 161 [Q3] → 173 (+12) [Q4]

1.2% less ownership

Funds ownership: 111.37% [Q3] → 110.17% (-1.2%) [Q4]

28% less capital invested

Capital invested by funds: $1.32B [Q3] → $949M (-$368M) [Q4]

65% less call options, than puts

Call options by funds: $1.19M | Put options by funds: $3.41M

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $8 40% upside
• Avg. target: $13 127% upside
• High target: $17 197% upside

3 analyst ratings

• positive: 2 67%
• neutral: 1 33%
• negative: 0 0%

Scotiabank Louise Chen 32% 1-year accuracy 43 / 133 met price target	197% upside $17	Sector Outperform Initiated	7 Mar 2025
Baird Joel Beatty 42% 1-year accuracy 16 / 38 met price target	40% upside $8	Neutral Maintained	27 Feb 2025
HC Wainwright & Co. Robert Burns 15% 1-year accuracy 26 / 171 met price target	145% upside $14	Buy Maintained	14 Jan 2025